First-Line Treatment for Adolescents with Depression

Treatment Algorithm Based on Severity

The American Academy of Pediatrics recommends psychotherapy, specifically cognitive-behavioral therapy (CBT) or interpersonal psychotherapy for adolescents (IPT-A), as the first-line treatment for adolescents with mild to moderate depression in the primary care setting 1, 2
For adolescents with mild depression, consider a period of active support and monitoring before starting evidence-based treatment, and if treatment is needed, begin with psychotherapy (CBT or IPT-A) 1, 3, 4
Common sense approaches should be incorporated, including physical exercise, sleep hygiene, and adequate nutrition, for adolescents with mild depression 4

CBT and IPT-A have demonstrated effectiveness in treating adolescent depression, with IPT-A showing significant effects on reducing depression severity, suicidal ideation, and hopelessness compared to treatment as usual 1, 4, 6
Computerized CBT (CCBT) interventions have also shown positive results, including in primary care settings, for adolescents with depression 2

Fluoxetine has the strongest evidence base for use in adolescents with depression, with response rates ranging from 47% to 69% compared to 33% to 57% for placebo 7, 3
The FDA has approved fluoxetine for children and adolescents with depression, and it should be started at lower doses than adult recommendations and titrated carefully 8

Monitor closely for adverse events with antidepressants, especially during the first few months of treatment, and be aware that suicidal thoughts and behaviors may emerge or worsen during early phases of antidepressant treatment 8
Adverse effects, such as nausea, headaches, and behavioral activation, are common with antidepressants, and duloxetine, venlafaxine, and paroxetine have higher rates of intolerable side effects and should not be first-line choices 5, 7

Regular contact after initiating treatment is essential to review understanding and adherence, monitor for emergence of adverse events, particularly suicidal ideation, and slowly taper SSRIs when discontinued to avoid withdrawal effects 8

Starting antidepressants at adult doses rather than lower recommended adolescent doses can increase the risk of adverse events, and inadequate duration of treatment trials before concluding ineffectiveness can lead to premature discontinuation of effective treatment 8